1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, 68(6):394–424.
2.Kano M, Hayano K, Hayashi H, Hanari N, Gunji H, Toyozumi T, Murakami K, Uesato M, Ota S, Matsubara H: Survival Benefit of Neoadjuvant Chemotherapy with S–1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis. Ann Surg Oncol 2019, 26(6):1805–1813.
3.Coimbra FJF, de Jesus VHF, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, Felismino T, Mello CAL, Almeida MF, Begnami M et al: Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery. Ann Surg Oncol 2019, 26(11):3618–3626.
4.Deng Y, Zhao Y, Fan W, Peng J, Luo X, Mo Y, Xiao B, Zhang L, Pan Z: Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection. J Cancer 2019, 10(21):5049–5056.
5.Reim D, Choi YS, Yoon HM, Park B, Eom BW, Kook MC, Ryu KW, Choi IJ, Joo J, Kim YW: Alpha-fetoprotein is a significant prognostic factor for gastric cancer: Results from a propensity score matching analysis after curative resection. Eur J Surg Oncol 2017, 43(8):1542–1549.
6.Xiao J, Ye ZS, Wei SH, Zeng Y, Lin ZM, Wang Y, Teng WH, Chen LC: Prognostic significance of pretreatment serum carcinoembryonic antigen levels in gastric cancer with pathological lymph node-negative: A large sample single-center retrospective study. World J Gastroenterol 2017, 23(48):8562–8569.
7.Tokunaga R, Imamura Y, Nakamura K, Uchihara T, Ishimoto T, Nakagawa S, Iwatsuki M, Baba Y, Sakamoto Y, Miyamoto Y et al: Carbohydrate antigen 19–9 is a useful prognostic marker in esophagogastric junction adenocarcinoma. Cancer Med 2015, 4(11):1659–1666.
8.Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J: Clinical significance of CA125 and CA72–4 in gastric cancer with peritoneal dissemination. Gastric Cancer 2012, 15(2):154–161.
9.Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y: Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014, 17(1):26–33.
10.Matsuoka T, Yashiro M: Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol 2018, 24(26):2818–2832.
11.Zou L, Qian J: Decline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinoma. Chin J Cancer Res 2014, 26(4):404–409.
12.Sun Z, Zhang N: Clinical evaluation of CEA, CA19–9, CA72–4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol 2014, 12:397.
13.Kim DH, Yun HY, Ryu DH, Han HS, Han JH, Yoon SM, Youn SJ: Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients. World J Gastroenterol 2015, 21(4):1216–1221.
14.Huang Z, Zhai XM, Wang H, Deng QT, Li K, Liu BS, Wang G, Liu TC: Simultaneous quantitation of carbohydrate antigen 125 and carcinoembryonic antigen in human serum via time-resolved fluoroimmunoassay. Clin Chim Acta 2018, 483:222–226.
15.Namikawa T, Kawanishi Y, Fujisawa K, Munekage E, Iwabu J, Munekage M, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K: Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer. Surg Today 2018, 48(4):388–394.
16.Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G, Guo M, Lian X, Fan D, Zhang H: Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer. BMC Cancer 2017, 17(1):737.
17.Wada N, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y: The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19–9 levels in gastric cancer cases. Surg Today 2017, 47(2):227–232.
18.Suenaga Y, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H et al: Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World J Gastrointest Oncol 2019, 11(1):17–27.
19.Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, Liu H, Mo X, Chen J, Zhang L: Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19–9 and CA 72–4 levels in gastric and colorectal cancer patients. J Cancer 2018, 9(3):494–501.
20.Jiang Y, Li T, Liang X, Hu Y, Huang L, Liao Z, Zhao L, Han Z, Zhu S, Wang M et al: Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer. JAMA Surg 2017, 152(7):e171087.
21.Hu PJ, Chen MY, Wu MS, Lin YC, Shih PH, Lai CH, Lin HJ: Clinical Evaluation of CA72–4 for Screening Gastric Cancer in A Healthy Population: A Multicenter Retrospective Study. Cancers (Basel) 2019, 11(5).
22.Jing J, Ge M, Yang Z, Li P: Spatial distribution characteristics of tumor marker CA724 reference values in China. Cancer Med 2019, 8(9):4465–4474.
23.Yang AP, Liu J, Lei HY, Zhang QW, Zhao L, Yang GH: CA72–4 combined with CEA, CA125 and CAl9–9 improves the sensitivity for the early diagnosis of gastric cancer. Clin Chim Acta 2014, 437:183–186.
24.Park JW, Lim SB, Kim DY, Jung KH, Hong YS, Chang HJ, Choi HS, Jeong SY: Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys 2009, 74(3):810–817.